Clinicians do not administer reactive TDM or objective disease activity assessments prior to making changes in biologic therapies in almost a third of patients with IBD.
After two decades of using biologics for IMIDs, we now have an armamentarium, including five drugs and a number of biosimilars, that continues to grow at a record pace.
Whether you plan to complete the entire series or prefer to pick a handful of individual webcasts most relevant to your practice, don’t miss this complimentary educational opportunity.
Denosumab and romosozumab work on different pathways but offer new options for patients with low bone mass as primary therapy and for those unresponsive to or contraindicated for bisphosphonates.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Individuals with clinically unapparent HBV and concomitant immune-mediated inflammatory diseases (IMIDs) (e.g., rheumatoid arthritis, psoriasis, inflammatory bowel disease and others) are particularly vulnerable to HBV reactivation when immunosuppressed.
Primary Vasculitides: Best Practices and Future Advances, a one day symposium on April 5, 2017, will explore Giant Cell Arteritis and other forms of vasculitis.
When this CME summit was last offered two years ago, it drew hundreds of attendees from over 30 states and nine countries. Even more are expected this time. Here’s why you should be among them.